Tribunal finds Ranbaxy promoters concealed US probes from buyer Daiichi
Ranbaxy Laboratories (Daiichi Sankyo v. Malvinder and Shivinder Singh) · Pharmaceuticals
The case in brief
Visible before detection
Checks that could have surfaced it, on hindsight
Regulatory & litigation records
Would have pulled FDA and DOJ records directly.
Can mislead when: Court records lag and name spellings vary. A clean record can mean the problem has not reached court yet.
Document authenticity / direct pull
Would have requested internal regulatory reports rather than summaries.
Can mislead when: The company can refuse consent, and a refusal is itself a flag. Some banks and co-op banks are not on AA yet.
Governance signals
Would have tested seller disclosures against whistleblower history.
Can mislead when: Private companies file late, so these signals are lagging. Kubr uses them to support other flags, not to prove anything alone.
Where Kubr services would have helped
IC note
Offered in India- C5 Would have requested internal regulatory reports rather than summaries.
- C8 Would have pulled FDA and DOJ records directly.
- C11 Would have tested seller disclosures against whistleblower history.
Verified Snapshot
Offered in India- C8 Would have pulled FDA and DOJ records directly.
- C11 Would have tested seller disclosures against whistleblower history.
Legal diligence support
Offered in India- C8 Would have pulled FDA and DOJ records directly.
- C11 Would have tested seller disclosures against whistleblower history.
Promoter profiles
Offered in India- C8 Would have pulled FDA and DOJ records directly.
- C11 Would have tested seller disclosures against whistleblower history.
Mapped from the checks each service runs. A hindsight reading of public records, not a promise that the failure would have been found.
Same pattern
A summary of public documents. It reports what the sources say. It is not Kubr's finding and not a statement of guilt.